Recent evidence challenges the notion that blinding to treatment assignment is necessary for placebos to be effective. This study aimed to compare open-label placebos (OLPs) with no-pill control (NPC) and double-blind placebos (DBPs) in treating irritable bowel syndrome (IBS).